The median duration of response was 14.7 months.
The overall response rate was 56% in patients with angioimmunoblastic T-cell lymphoma.
Axicabtagene ciloleucel was associated with higher rates of grade 3-5 ICANS and corticosteroid use.
Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”
Adding romidepsin to CHOEP did not improve progression-free survival in transplant-eligible, newly diagnosed peripheral T-cell lymphoma.
Researchers sought to determine whether umbralisib plus ublituximab would be safe and active in patients with relapsed/refractory marginal zone lymphoma.